Physical check-ups among athletes with valvular heart disease are of significant relevance.

Background: Aortic stenosis is the most common valvular heart disease in the United States.

Mitral regurgitation (MR) is the most frequent valvular heart disease in developed countries.

Patients with coronary heart disease, valvular heart disease, or cardiomyopathy were excluded from the study.

Objective: Serotonergic appetite suppressants and ergot-derived dopamine agonists have been associated with drug-induced valvular heart disease.

Several predisposing substrates such as increasing age, heart failure, hypertension and valvular heart disease have been identified.

Conclusions: There was a consistent, significant association between many medications that affect serotonergic pathways and valvular heart disease.

The potential of MRI to study both the anatomic and functional consequences of valvular heart disease warrants further study.

This was of a woman who had suffered from rheumatic fever in adolescence and consequentially developed valvular heart disease.

Aims: The prognostic role of tricuspid regurgitation (TR) associated with organic left-sided valvular heart disease is well known.

Aortic valve stenosis (AS) is the most common valvular heart disease, and valve replacement is the only definitive treatment.

Conclusion: Even in persons without valvular heart disease or heart failure, an elevated level of BNP predicts recurrence of AF after ECV.

Symptomatic athletes and those with severe valvular heart disease, impaired ventricular function, pulmonary hypertension and arrhythmias should refrain from most competitive sports.

Methods: We have screened consecutive patients attending for cardioversion of AF and recruited those without valvular heart disease, heart failure or permanent pacemakers.

We successfully performed a concomitant operation in a patient with severe valvular heart disease with a giant left atrium and a pulmonary cancer.

The purpose of this meta-analysis is to synthesise the current evidence of a link between several medications affecting sertonergic pathways and valvular heart disease.